Nivolumab-induced Stevens-Johnson syndrome: Not only due to PD-1 inhibition-Reference-Cited by-同舟云学术

Nivolumab-induced Stevens-Johnson syndrome: Not only due to PD-1 inhibition

Published:2023-09 Issue:9 Volume:11 Page:2936-2938.e1
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Rodríguez-Otero Natalia^ORCID,Chamorro-Pérez Jesús,Fernández-Lozano Carlos,Elías-Sáenz Isabel,Berná-Rico Emilio,de Nicolás-Ruanes Belén,Meléndez-Gispert María Rosa,Moreno-García del Real Carmen,Martínez-Botas Javier,Cortés-Salgado Alfonso,Solano-Solares Emilio^ORCID

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference9 articles.

1. Stevens-Johnson syndrome and toxic epidermal necrolysis–like reactions to checkpoint inhibitors: a systematic review;Maloney;Int J Dermatol,2020

2. Cutaneous adverse reactions to anti-PD-1 treatment—a systematic review;Simonsen;J Am Acad Dermatol,2020

3. Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer;Koshizuka;Clin Case Rep,2021

4. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment;Cabañas;Clin Exp Allergy,2018

5. Nivolumab-associated DRESS in a genetic susceptible individual;Ai;J Immunother Cancer,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review;Frontiers in Immunology;2024-07-12

2. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy;Journal of Inflammation Research;2024-04